The Readout Loud
343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
It’s a STAT reporter two-fer guest episode. First, Lizzy Lawrence joins from D.C. to dish on the upheaval and drama taking place at the FDA. Then, we chat with Jason Mast about Bluebird Bio, its fire sale to private equity and what lies ahead for the unsettled world of genetic medicines. Before those discussions, Allison provides some insight into the “new kids” on the biotech VC block.